NS Pharma
Manufacturing · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
140 E Ridgewood Ave Ste 280S, Paramus, N...Phone Number
(201) 986-3860Website
www.nspharma.comRevenue
$12.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About NS Pharma
NS Pharma is a research-driven biopharmaceutical company focused on developing innovative treatments for rare diseases, particularly Duchenne Muscular Dystrophy and eosinophilic granulomatosis with polyangiitis (EGPA). As a subsidiary of Nippon Shinyaku Co., Ltd. in Japan, they utilize advanced scientific approaches such as exon-skipping and JAK1 inhibition to create effective therapies. Their target clients include patients suffering from rare neurological and inflammatory diseases. NS Pharma is committed to improving the lives of these patients through thoughtful science and community engagement.Explore more
NS Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is NS Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if NS Pharma had a recent Job posting/layoffs
Check if NS Pharma has recently received funding, and reach out quickly before it becomes old news!
Check out if NS Pharma is spiking on competitors!
Funding: Get notified immidiatlly once NS Pharma has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when NS Pharma launches new products
Earning: See what the market has to say on NS Pharma recently announced quarterly report
NS Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at NS Pharma
Recommended Actions
Find VP level buyers at NS Pharma
Find more new buyers
Compare Similar Companies to NS Pharma
Compare insights from companies similar to NS Pharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
NS Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
NS Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about NS Pharma.
NS Pharma Tech Stack
A closer look at the technologies used by NS Pharma
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Partnership, Product Development, Research & Development, Business Development, Medical Research
Hiring Plans
NS Pharma has more open roles in Sales than it has had at any time in the past 12 months.
Hiring Plans
Open Position
NS Pharma News & Media
Brogidirsen (NS-089/NCNP-02) 3.5 Year Clinical Trial Data for the Treatment of Duchenne Muscular Dystrophy Presented at 2025 World Muscle Society Congress
PARAMUS, N.J., Oct. 14, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma), a biopharmaceutical leader in rare disease and subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that the National Center of Neurology and Psychiatry (NCNP, Kodaira City; President, Kazuyuki...FDA Grants Orphan Drug Designation to NS-051/NCNP-04 for the Treatment of Duchenne Muscular Dystrophy
PARAMUS, N.J., Sept. 19, 2025 /PRNewswire/ -- NS Pharma, Inc. announced today that the U.S. Food & Drug Administration (FDA) has granted Orphan Drug Designation to NS-051/NCNP-04 which is being developed for the treatment of Duchenne muscular dystrophy (Duchenne) in patients amenable to...FDA Grants Fast Track Designation to NS-229 for the Treatment of Eosinophilic Granulomatosis with Polyangiitis
PARAMUS, NJ., Sept. 9, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma) a subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), announced today that the U.S Food & Drug Administration (FDA) has granted Fast Track designation to NS-229, which is being developed for the treatment of...NS Pharma Announces Strategic Alliance with Boston Children's Hospital to Develop New Therapies for Rare Diseases
PARAMUS, N.J., July 1, 2025 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma) announced today that its parent company, Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), headquartered in Kyoto, Japan, has finalized a strategic partnership with Boston Children's Hospital (Boston Children's)...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding NS Pharma
Sign Up For FreeTo access detailed company insights
NS Pharma is a research-driven biopharmaceutical company focused on developing innovative treatments for rare diseases, particularly Duchenne Muscular Dystrophy and eosinophilic granulomatosis with polyangiitis (EGPA). As a subsidiary of Nippon Shinyaku Co., Ltd. in Japan, they utilize advanced scientific approaches such as exon-skipping and JAK1 i... Read More
